Page 189 - Read Online

Rewisha et al. 16 case series of HCC post DAAs

angiogenic HCC bio-markers. of evidence of an effect of direct-acting antivirals on the recurrence of
hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol
In conclusion, surveillance programs should be widely 2016;65:734-40.
endorsed during and after DAAs therapy for patients 6. Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D,
Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D,
at HCC risk, even for those who had been achieved Kennedy N, Morris J, Fraser A, Stanley A, Bramley P, Hutchinson
HCV cure. Perhaps IFN still has a role -- using it as a SJ. Mortality in hepatitis C patients who achieve a sustained
backbone therapy might benefit patients at the highest viral response compared to the general population. J Hepatol
risk of HCC. 2017;66:19-27.
7. Bailly F, Pradat P, Virlogeux V, Zoulim F. Antiviral therapy in patients
DECLARATIONS with hepatitis C virus-induced cirrhosis. Dig Dis 2015;33:613-23.
8. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R,
Authors’ contributions Stättermayer AF, Beinhardt S, Graziadei I, Freissmuth C, Maieron A,
Gschwantler M, Strasser M, Peck-Radosalvjevic M, Trauner M, Hofer
Idea and study design: E.A. Rewisha H, Ferenci P. Unexpected high incidence of hepatocellular carcinoma
Collection of literature data: O. Elshaarawy, D.M. in cirrhotic patients with SVR following IFN-free DAA treatment. J
Elsabaawy Hepatol 2016;65:856-8.
Data analysis: A. Abdelah 9. Serti E, Park H, Keane M, O’Keefe AC, Rivera E, Liang TJ, Ghany
Clinical data collection, manuscript writing and critical M, Rehermann B. Rapid decrease in hepatitis C viremia by direct
revision: O.M. Alhaddad, M.M. Elsabaawy acting antivirals improves the natural killer cell response to IFN. Gut
2017;66:724-35.
Financial support and sponsorship 10. Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D,
None. McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K,
Remaley AT, Masur H, Kottilil S. Effect of sofosbuvir and ribavirin
treatment on peripheral and hepatic lipid metabolism in chronic HCV,
Conflicts of interest genotype-1 infected patients. Hepatology 2015;61:790-801.
There are no conflicts of interest. 11. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert
F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S,
Patient consent Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association
A written informed consent was obtained from all between sustained virological response and all-cause mortality among
participants in the study. patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA
2012;308:2584-93.
Ethics approval 12. Hsu CS, Chao YC, Lin HH, Chen DS, Kao JH. Systematic review:
The study protocol was approved by the Institutional impact of interferon-based therapy on HCV-related hepatocellular
carcinoma. Sci Rep 2015;5:9954.
Review Board (IRB) and local ethical committee of the 13. Pasquali S, Mocellin S. The anticancer face of interferon alpha (IFN-
National Liver Institute, Menoufia University. alpha): from biology to clinical results, with a focus on melanoma.
Curr Med Chem 2010;17:3327-36.
REFERENCES 14. Nelson MH, Paulos CM. Novel immunotherapies for hematologic
malignancies. Immunol Rev 2015;263:90-105.
1. Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular 15. Zhao J, Wang M, Li Z, Gao D, Cai Y, Chang J, Wang SH. Interferon-
carcinoma. Clin Mol Hepatol 2015;21:105-14. alpha-2b induces autophagy in hepatocellular carcinoma cells through
2. de Oliveria Andrade LJ, D’Oliveira A, Melo RC, De Souza EC, Beclin1 pathway. Cancer Biol Med 2014;11:64-8.
Costa Silva CA, Paraná R. Association between hepatitis C and 16. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F,
hepatocellular carcinoma. J Glob Infect Dis 2009;1:33-7. Yang J, Zhang Q, Wang X, He C, Pan H. Autophagy and chemotherapy
3. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, resistance: a promising therapeutic target for cancer treatment. Cell
Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns Death Dis 2013;4:e838.
X, Bruix J. Unexpected high rate of early tumor recurrence in patients 17. Liang KH, Hsu CW, Chang ML, Chen YC, Lai MW, Yeh CT.
with HCV-related HCC undergoing interferon-free therapy. J Hepatol Peginterferon is superior to nucleos(t)ide analogues for prevention
2016;65:719-26. of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis
4. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, 2016;213:966-74.
Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti 18. Mandorfer M, Kozbial K, Schwabl PH, Freissmuth C, Schwarzer
S. Early occurrence and recurrence of hepatocellular carcinoma in R, Stern R, Chromy D, Stättermayer A, Reiberger TH, Beinhardt
HCV-related cirrhosis treated with direct acting antivirals. J Hepatol S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-
2016;65:727-33. Radosavljevic M. Sustained virologic response to interferon-free
5. ANRS collaborative study group on hepatocellular carcinoma (ANRS therapies ameliorates HCV-induced portal hypertension. J Hepatol
CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack 2016;65:692-9.

Hepatoma Research ¦ Volume 3 ¦ August 11, 2017 181